Your browser doesn't support javascript.
loading
The efficacy of botulinum toxin for the treatment of trigeminal and postherpetic neuralgia: a systematic review with meta-analyses.
Shackleton, Thomas; Ram, Saravanan; Black, Misty; Ryder, Jon; Clark, Glenn T; Enciso, Reyes.
  • Shackleton T; Graduate, Master Science Program in Orofacial Pain and Oral Medicine, Herman Ostrow School of Dentistry of USC, Los Angeles, CA, USA.
  • Ram S; Associate Professor of Clinical Dentistry, Program Director, Oral Medicine, Herman Ostrow School of Dentistry of USC, Los Angeles, CA, USA.
  • Black M; Graduate, Master Science Program in Orofacial Pain and Oral Medicine, Herman Ostrow School of Dentistry of USC, Los Angeles, CA, USA.
  • Ryder J; Graduate, Master Science Program in Orofacial Pain and Oral Medicine, Herman Ostrow School of Dentistry of USC, Los Angeles, CA, USA.
  • Clark GT; Professor of Dentistry, Program Director, Orofacial Pain, Herman Ostrow School of Dentistry of USC, Los Angeles, CA, USA.
  • Enciso R; Associate Professor of Clinical Dentistry, Herman Ostrow School of Dentistry of USC, Los Angeles, CA, USA. Electronic address: Renciso@usc.edu.
Article en En | MEDLINE | ID: mdl-27260275
ABSTRACT

OBJECTIVE:

To evaluate the efficacy of a botulinum toxin type A (BoTN-A) in treating trigeminal neuralgia (TN) and postherpetic neuralgia (PHN). STUDY

DESIGN:

Three databases were searched Medline, Web of Science, and Cochrane Library. The search was restricted to English-language randomized, placebo-controlled trials. Three review authors evaluated the cases for risk of bias.

RESULTS:

Six studies were eligible for inclusion. Pooled results showed a difference in post-treatment pain intensity of -3.009 (95% confidence interval -4.566 to -1.453; P < .001) in favor of BoTN-A compared with placebo in managing TN or PHN. Of the six studies, five had unclear risk of bias, and one showed high risk.

CONCLUSIONS:

Although the studies had unclear or high risk of bias, moderate evidence regarding the efficacy of BoTN-A in treating TN and PHN was found. BoTN-A might be an alternative treatment to those patients who are either unable to manage their pain medically or would like adjunct therapy.
Asunto(s)

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neuralgia del Trigémino / Toxinas Botulínicas Tipo A / Neuralgia Posherpética / Fármacos Neuromusculares Tipo de estudio: Clinical_trials / Systematic_reviews Límite: Humans Idioma: En Año: 2016 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neuralgia del Trigémino / Toxinas Botulínicas Tipo A / Neuralgia Posherpética / Fármacos Neuromusculares Tipo de estudio: Clinical_trials / Systematic_reviews Límite: Humans Idioma: En Año: 2016 Tipo del documento: Article